VivoSeq
Infectious Disease

Candidiasis

39

Pipeline Programs↗

5

Active Trials↗

25

Companies Involved↗

Candidiasis is a moderately active landscape with 39 programs across 25 companies. The most active players are Fujian Shengdi Pharmaceutical Co., Ltd., Astellas, Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). 11 therapies are approved with 16 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

56/100

Pipeline Velocity

6/100

Mech. Concentration

55/100

Completion Rate

87/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

F

Fujian Shengdi Pharmaceutical Co., Ltd.

2 programs

Phase 2Astellas logo

Astellas

1 program

Phase 2C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Phase 2K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 2Boehringer Ingelheim logo

Boehringer Ingelheim

2 programs

Phase 3T

Thinq Pharma-CRO Pte. Ltd.

2 programs

Phase 3

Pipeline

Programs by Phase

Preclinical3

Caspofungin Acetate

Merck & Co.

Tests for Candidiasis

Centre Hospitalier Universitaire de Nīmes

Preemptive Therapy With Anidulafungin

Duke University

Phase 11

Nitric Oxide

Mallinckrodt

Phase 28

Posaconazole

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Amphotericin B

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

VT-1161

Viamet

FK463

Astellas

HRS9432

Fujian Shengdi Pharmaceutical Co., Ltd.

Phase 316

Clotrimazole

Bayer

Nystatin

Good Molecules, LLC

Ketoconazole

Wim Janssens

Amphotericin B Deoxycholate

Merck & Co.

Fosmanogepix

Basilea Pharmaceutica

Approved11

Fluconazole

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Micafungin

Baxter Healthcare Corporation

Caspofungin

Fresenius Kabi Oncology Ltd.

Anidulafungin

Vicuron Pharmaceuticals

Voriconazole

Prism Pharmaceuticals

Analysis

Trial Status

62

clinical trials

Completed47 · 76%
Terminated7 · 11%
Recruiting4 · 6%
Unknown status3 · 5%
Not yet recruiting1 · 2%

Clinical Trials

Trial Activity

62 trials

A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis
Recruiting·FFujian Shengdi Pharmaceutical Co., Ltd.·Phase 2·NCT06194201·40 enrolled
Study Comparing Caspofungin to Placebo for the Treatment of ICU Intra-abdominal Candidiasis
Recruiting·—·Phase 3·NCT03580733·448 enrolled
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
Recruiting·Basilea Pharmaceutica logoBasilea Pharmaceutica·Phase 3·NCT05421858·450 enrolled
The Natural History and Pathogenesis of Human Fungal Infections
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT01386437·1,200 enrolled
Pharmacokinetic Study of Rezafungin in Patients With Suspected Intra-Abdominal Candidiasis
Not yet recruiting·FFundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal·Phase 4·NCT06985758·20 enrolled
Gentian Violet Vs. Nystatin Oral Suspension for Treatment of Oropharyngeal Candidiasis
Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 3·NCT01427738·221 enrolled
Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia
Completed·Astellas logoAstellas·Phase 3·NCT00106288·637 enrolled
A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)
Completed·VViamet·Phase 2·NCT01891331·55 enrolled
Efficacy and Safety Study of Miconazole Lauriad to Treat Oropharyngeal Candidiasis in HIV Patients
Completed·VValerio Therapeutics·Phase 3·NCT00390780·578 enrolled
Comparative Trial of Micafungin Versus Fluconazole for Treating Esophageal Candidiasis
Completed·Astellas logoAstellas·Phase 3·NCT00666185·523 enrolled
A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus
Completed·CCSPC Ouyi Pharmaceutical Co., Ltd.·Phase 3·NCT05707832·31 enrolled
Single Dose Versus Two Weeks Course of Fluconazole in the Treatment of Oropharyngeal Candidiasis in HIV Infected Individuals in Tanzania
Completed·NNetherlands Organisation for Scientific Research·Phase 4·NCT00553137·220 enrolled
Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis
Completed·Astellas logoAstellas·Phase 2·NCT00036179·75 enrolled
Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)
Completed·SScynexis, Inc.·Phase 3·NCT03363841·30 enrolled
Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis
Completed·Pfizer logoPfizer·Phase 4·NCT00496197·282 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)